Clinical

Articles

A recent study provides evidence showing that focal 22q11.22 deletions may be correlated with poor outcomes in patients with pediatric B-cell acute lymphoblastic leukemia with alterations in IKZF1.

Focal 22q11.22 Deletions Associated With Poor Outcomes in Pediatric B-Cell Acute Lymphoblastic Leukemia With IKZF1 Alterations

Pediatric patients with low-risk acute lymphoblastic leukemia may be able to omit treatment with vincristine and dexamethasone pulse therapy after the first year of treatment.

Vincristine/Dexamethasone Pulse Therapy May be Omitted After 1 Year of Treatment in Pediatric Acute Lymphoblastic Leukemia

Racial and ethnic disparities in incidence and risk of childhood cancer have been identified across a number of malignancies.

Study on Racial and Ethnic Disparities in Pediatric Cancer Identify Difference in Risk Between Patient Subgroups

KEY POINTS
• Synovial sarcomas are often mistreated with unplanned tumor resection.
• Attention from specialists early in the course of SS can minimize the risk of recurrence, metastases, and the necessity for resurgery, all of which are increased with unplanned tumor resection.
• Chemotherapy alone does not provide sufficient local control of the tumor. 
• Resurgery, in conjunction with radiotherapy and chemotherapy, is the best choice of management for this patient. 

Pediatric Locally Advanced Synovial Sarcoma: What Would Be the Best Treatment Option?

Based on recent study results, investigators recommended TBI plus etoposide for patients older than 4 years of age with high-risk ALL undergoing allogeneic hematopoietic stem cell transplantation. 

TBI Plus Etoposide Prior to HSCT Leads to Improved OS, Lower Relapse Risk in High-Risk Pediatric ALL

Videos

“As the number of AYA survivors continues to grow, there is a pressing need for targeted information, education, and intervention around sexual health, intimate relationships, and body image,” the Children’s Oncology Group (COG) AYA Oncology Discipline Committee wrote in a review.

Gwendolyn P. Quinn, PhD, on Sexual Health in AYA Cancer Survivors

Payne and colleagues indicated that a significant number of adolescent and young adult women are still not being given the information they desire regarding fertility preservation and therefore are not making fully informed treatment decisions. 

Jackelyn B. Payne, MPH, MA, on Fertility Preservation in AYAs with Cancer

The FDA granted accelerated approval to naxitamab-gqgk (Danyelza) in combination with GM-CSF for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.

FDA Grants Accelerated Approval to Naxitamab-gqgk Combo for the Treatment of Neuroblastoma

A study found that radiation therapy to treat childhood abdominal and pelvic cancers potentially caused body composition abnormalities and worse cardiometabolic health for adult survivors compared to the general public.

Radiation May Cause Body Composition Abnormalities in Adult Survivors of Pediatric Cancer

This study is intended to “investigate how chemotherapy disrupts sensory processing, memory, and attention in children; where in the brain the damage is occurring; and whether there is a biomarker that can identify those who are most vulnerable.”

Pediatric Cancers | Topics